Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib

ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, ONDREJ TOPOLCAN, JAROSLAV RACEK, MARTIN SVATON, RADEK KUCERA, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RENATA CHLOUPKOVA, ALEXANDR POPRACH and TOMAS BUCHLER
Anticancer Research May 2016, 36 (5) 2459-2465;
ONDREJ FIALA
1Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fiala.o@centrum.cz
MILOS PESEK
3Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JINDRICH FINEK
1Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ONDREJ TOPOLCAN
4Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAROSLAV RACEK
5Istitute of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARTIN SVATON
3Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RADEK KUCERA
4Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAREK MINARIK
6Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic
7Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUCIE BENESOVA
6Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZBYNEK BORTLICEK
8Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RENATA CHLOUPKOVA
8Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDR POPRACH
9Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMAS BUCHLER
10Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 36 no. 5 2459-2465
PubMed 
27127158

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received February 20, 2016
  • Revision received April 2, 2016
  • Accepted April 4, 2016
  • Published online April 28, 2016.

Copyright & Usage 
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. ONDREJ FIALA1,2⇑,
  2. MILOS PESEK3,
  3. JINDRICH FINEK1,
  4. ONDREJ TOPOLCAN4,
  5. JAROSLAV RACEK5,
  6. MARTIN SVATON3,
  7. RADEK KUCERA4,
  8. MAREK MINARIK6,7,
  9. LUCIE BENESOVA6,
  10. ZBYNEK BORTLICEK8,
  11. RENATA CHLOUPKOVA8,
  12. ALEXANDR POPRACH9 and
  13. TOMAS BUCHLER10
  1. 1Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  2. 2Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  3. 3Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  4. 4Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  5. 5Istitute of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
  6. 6Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic
  7. 7Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic
  8. 8Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  9. 9Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic
  10. 10Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
  1. Correspondence to: Ondrej Fiala, MUDr, PhD, Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University Prague, alej Svobody 80, CZ-304 60 Pilsen, Czech Republic. Tel: +42 0728655488, e-mail: fiala.o{at}centrum.cz
View Full Text

Cited By...

  • 16 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 36 (5)
Anticancer Research
Vol. 36, Issue 5
May 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, ONDREJ TOPOLCAN, JAROSLAV RACEK, MARTIN SVATON, RADEK KUCERA, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RENATA CHLOUPKOVA, ALEXANDR POPRACH, TOMAS BUCHLER
Anticancer Research May 2016, 36 (5) 2459-2465;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, ONDREJ TOPOLCAN, JAROSLAV RACEK, MARTIN SVATON, RADEK KUCERA, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RENATA CHLOUPKOVA, ALEXANDR POPRACH, TOMAS BUCHLER
Anticancer Research May 2016, 36 (5) 2459-2465;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • lactate dehydrogenase
  • LDH
  • Lung cancer
  • NSCLC
  • EGFR-TKI
  • erlotinib
  • prediction
  • biomarker
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire